Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease
Document Type
Article
Abstract
Background: The status of nerve growth factor (NGF) levels during the prodromal phase of Alzheimer disease (AD), characterized by mild cognitive impairment (MCI), remains unknown. Objective: To investigate whether cortical and/or hippocampal NGF levels are altered in subjects with MCI or different levels of AD severity. Design and Main Outcome Measures: An NGF enzyme-linked immunosorbent assay determined protein levels in the hippocampus and 5 cortical areas in people clinically diagnosed as having no cognitive impairment, MCI, mild AD, or severe AD. Setting and Patients: Subjects were from the Rush Religious Orders Study and the University of Pittsburgh Alzheimer's Disease Research Center (Pittsburgh, Pa). Results: We found no changes in cortical or hippocampal NGF levels across groups; in MCI, levels did not correlate with an increase in choline acetyltransferase activity in these regions. Conclusion: Brain NGF levels appear sufficient to support the cholinergic plasticity changes seen in MCI and remain stable throughout the disease course.
Publication Date
8-1-2003
Publication Title
Archives of Neurology
ISSN
00039942
Volume
60
Issue
8
First Page
1143
Last Page
1148
PubMed ID
12925373
Digital Object Identifier (DOI)
10.1001/archneur.60.8.1143
Recommended Citation
Mufson, Elliott J.; Ikonomovic, Milos D.; Styren, Scot D.; Counts, Scott E.; Wuu, Joanne; Leurgans, Sue; Bennett, David A.; Cochran, Elizabeth J.; and DeKosky, Steven T., "Preservation of brain nerve growth factor in mild cognitive impairment and Alzheimer disease" (2003). Translational Neuroscience. 1920.
https://scholar.barrowneuro.org/neurobiology/1920
